Insulin's 85th anniversary-An enduring medical miracle

Diabetes Research and Clinical Practice

Volumn 78, Issue 2, 2007, Pages 149-158

  Heller, Simon ^a   Kozlovski, Plamen ^b   Kurtzhals, Peter ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Analogues; Delivery; Device; Insulin

Indexed keywords

GLUCOSE; HUMALOG MIX; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; COUGHING; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PURIFICATION; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; FORCED EXPIRATORY VOLUME; HISTORY OF MEDICINE; HUMAN; HYPOGLYCEMIA; INSULIN PUMP; INSULIN SYNTHESIS; INSULIN TREATMENT; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYRINGE;

AMINO ACID SEQUENCE; ANIMALS; DIABETES MELLITUS; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS;

EID: 34548847731     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2007.04.001     Document Type: Review

References (102)

1. Banting F., Best C., Collip J., Campbell W., and Fletcher A. Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 12 (1922) 141-146
2. Bliss M. The Discovery of Insulin (1982), McClelland and Stewart, Toronto
3. Bliss M. The history of insulin. Diabetes Care 16 Suppl. 3 (1993) 4-7
4. Banting F., and Best C. The internal secretion of the pancreas. J. Lab. Clin. Med. 7 (1922) 251-266
5. Chien Y.W. Human insulin: basic sciences to therapeutic uses. Drug Dev. Ind. Pharm. 22 (1996) 752-789
6. Ryle A., Sanger F., Smith L., and Kitai R. The disulphide bonds of insulin. Biochem. J. 60 4 (1955) 541-556
7. Stretton A.O. The first sequence. Fred Sanger and insulin. Genetics 162 2 (2002) 527-532
8. Yalow R.S., and Berson S.A. Immunoassay of endogenous plasma insulin in man 216. J. Clin. Invest. 39 (1960) 1157-1175
9. Poulsen J.E. The impact of August Krogh on the insulin treatment of diabetes and our present status. Acta Med. Scand. Suppl. 578 (1975) 7-14
10. Hagedorn H., Jensen B., Krarup N., and Wodstrup I. Protamine insulinate. J. Am. Med.Assoc. 106 (1936) 177-180
11. Scott D., and Fisher A. The effect of zinc salts on the action of insulin. J. Pharmacol. Exp. Ther. 55 (1935) 206
12. Felig P. Landmark perspective: protamine insulin. Hagedorn's pioneering contribution to drug delivery in the management of diabetes. J. Am. Med. Assoc. 251 3 (1984) 393-396
13. Korp W., and Levett R.E. Experiences with monocomponent insulin treatment. Wien Klin Wochenschr 85 18 (1973) 326-330
14. Bruni B., Ricci C., Giolitti A., Osenda M., D'Alberto M., and Turco G.L. Insulin antibody production studied quantitatively with a modified radioimmunoassay technique and with radioimmunoelectrophoresis in patients treated with monocomponent (MC) insulin. J. Nucl. Biol. Med. 17 3 (1973) 123
15. Owens D., Vora J., and Dolben J. Human insulin and beyond: semi-synthesis and recombinant DNA technology reviewed. In: Pickup J. (Ed). Biotechnology of Insulin Therapy (1991), Blackwell Scientific Publications, Oxford
16. Ladisch M.R., and Kohlmann K.L. Recombinant human insulin. Biotechnol. Prog. 8 6 (1992) 469-478
17. Chance R.E., and Frank B.H. Research, development, production, and safety of biosynthetic human insulin. Diabetes Care 16 Suppl. 3 (1993) 133-142
18. Owens D.R., Zinman B., and Bolli G.B. Insulins today and beyond. Lancet 358 9283 (2001) 739-746
19. Gerich J.E. Novel insulins: expanding options in diabetes management. Am. J. Med. 113 4 (2002) 308-316
20. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
21. Brange J., Ribel U., Hansen J.F., Dodson G., Hansen M.T., Havelund S., et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 333 6174 (1988) 679-682
22. Hirsch I.B. Insulin analogues. N. Engl. J. Med. 352 2 (2005) 174-183
23. McAulay V., and Frier B.M. Insulin analogues and other developments in insulin therapy for diabetes. Expert Opin. Pharmacother. 4 7 (2003) 1141-1156
24. Rave K., Klein O., Frick A.D., and Becker R.H. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 29 8 (2006) 1812-1817
25. ® Prescribing Information 2005. Aventis Pharmaceuticals Inc., Kansas City, MO, a member of the sanofi-aventis Group, Bridgewater, NJ.
26. Riddle M.C., Rosenstock J., and Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 11 (2003) 3080-3086
27. Heise T., Nosek L., Ronn B.B., Endahl L., Heinemann L., Kapitza C., et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53 6 (2004) 1614-1620
28. Ashwell S.G., Gebbie J., and Home P.D. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 23 8 (2006) 879-886
29. Havelund S., Plum A., Ribel U., Jonassen I., Volund A., Markussen J., et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 21 8 (2004) 1498-1504
30. Kurtzhals P., Havelund S., Jonassen I., Kiehr B., Larsen U.D., Ribel U., et al. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 312 Pt 3 (1995) 725-731
31. Pieber T., Plank J., Goerzer E., Sommer R., Wutte A., Sinner F., et al. Duration of action, pharmacodynamic profile and between-subject variability of insulin detemir in subjects with type 1 diabetes. Diabetes 51 Suppl. 2 (2002) A53
32. Lüddeke H.-J., Hansen J., Meriläinen M., and Gallwitz B. An evaluation of insulin detemir treatment in type 1 and type 2 diabetes: German cohort data from the PREDICTIVE™ study. Diabetologia 49 Suppl. 1 (2006) 596-597
33. Home P.D., Barriocanal L., and Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur. J. Clin. Pharmacol. 55 3 (1999) 199-203
34. Raskin P., Guthrie R.A., Leiter L., Riis A., and Jovanovic L. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23 5 (2000) 583-588
35. Raskin P., Klaff L., Bergenstal R., Halle J.P., Donley D., and Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23 11 (2000) 1666-1671
36. Perriello G., Pampanelli S., Porcellati F., Avogaro A., Bosi E., Petrella G., et al. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial. Diabet. Med. 22 5 (2005) 606-611
37. Heller S.R., Colagiuri S., Vaaler S., Wolffenbuttel B.H., Koelendorf K., Friberg H.H., et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet. Med. 21 7 (2004) 769-775
38. Heller S.R., Amiel S.A., and Mansell P. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 22 10 (1999) 1607-1611
39. Ashwell S.G., Amiel S.A., Bilous R.W., Dashora U., Heller S.R., Hepburn D.A., et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet. Med. 23 3 (2006) 285-292
40. Owens D.R., Coates P.A., Luzio S.D., Tinbergen J.P., and Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 23 6 (2000) 813-819
41. Plank J., Bodenlenz M., Sinner F., Magnes C., Gorzer E., Regittnig W., et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28 5 (2005) 1107-1112
42. Hermansen K., Fontaine P., Kukolja K.K., Peterkova V., Leth G., and Gall M.A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47 4 (2004) 622-629
43. Hermansen K., Davies M., Derezinski T., Martinez R.G., Clauson P., and Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29 6 (2006) 1269-1274
44. Hermansen K., Madsbad S., Perrild H., Kristensen A., and Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 24 2 (2001) 296-301
45. Ackermann R., Hansen J., and Nauck M. Basal-bolus therapy with insulin detemir/insulin aspart improves glycaemic control and reduces hypoglycaemia: data from the German cohort of the PREDICTIVE™ study. Diabetologia 49 Suppl. 1 (2006) 595
46. Rosenstock J., Davies M., Home P., Larsen J., Tamer S., and Schernthaner G. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes 55 Suppl. 1 (2006) A132
47. Boehm B.O., Home P.D., Behrend C., Kamp N.M., and Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med. 19 5 (2002) 393-399
48. Roach P., and Malone J.K. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with type 2 diabetes. Diabet Med. 23 7 (2006) 743-749
49. Garber A.J., Wahlen J., Wahl T., Bressler P., Braceras R., Allen E., et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes. Metab. 8 1 (2006) 58-66
50. Kabadi U.M., and Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res. Clin. Pract. 72 3 (2006) 265-270
51. Malone J.K., Bai S., Campaigne B.N., Reviriego J., and ugendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet. Med. 22 4 (2005) 374-381
52. Saudek C.D. Novel forms of insulin delivery. Endocrinol. Metab. Clin. North Am. 26 3 (1997) 599-610
53. Bohannon N.J. Insulin delivery using pen devices. Simple-to-use tools may help young and old alike. Postgrad. Med. 106 5 (1999) 57-64 68
54. Coscelli C., Lostia S., Lunetta M., Nosari I., and Coronel G.A. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res. Clin. Pract. 28 3 (1995) 173-177
55. Smits J., Schop C., and Blok G. A comparative study between two insulin pen injection devices. Acta Therapeutica 19 (1993) 15-22
56. Jefferson I.G., Marteau T.M., Smith M.A., and Baum J.D. A multiple injection regimen using an insulin injection pen and pre-filled cartridged soluble human insulin in adolescents with diabetes. Diabet. Med. 2 6 (1985) 493-495
57. Plevin S., and Sadur C. Use of a prefilled insulin syringe (Novolin Prefilled) by patients with diabetes. Clin. Ther. 15 2 (1993) 423-431
58. Graff M.R., and McClanahan M.A. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin. Ther. 20 3 (1998) 486-496
59. Pickup J.C., Keen H., Parsons J.A., and Alberti K.G. Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br. Med. J. 1 6107 (1978) 204-207
60. Pickup J. Continuous subcutaneous insulin infusion. In: Pickup J., and Williams G. (Eds). Textbook of Diabetes (1997), Blackwell Science, Oxford 34.1-34.12
61. Tamborlane W.V., Sherwin R.S., Genel M., and Felig P. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. N. Engl. J. Med. 300 11 (1979) 573-578
62. Bode B.W., Steed R.D., and Davidson P.C. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care 19 4 (1996) 324-327
63. Ng Tang F.S., Pickup J.C., Bending J.J., Collins A.C., Keen H., and Dalton N. Hypoglycemia and counterregulation in insulin-dependent diabetic patients: a comparison of continuous subcutaneous insulin infusion and conventional insulin injection therapy. Diabetes Care 9 3 (1986) 221-227
64. Koivisto V.A., Yki-Jarvinen H., Helve E., Karonen S.L., and Pelkonen R. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 35 1 (1986) 78-82
65. Bode B.W., Tamborlane W.V., and Davidson P.C. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad. Med. 111 5 (2002) 69-77
66. Klonoff D.C. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 28 5 (2005) 1231-1239
67. Chico A., Vidal-Rios P., Subira M., and Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 26 4 (2003) 1153-1157
68. Melki V., Ayon F., Fernandez M., and Hanaire-Broutin H. Value and limitations of the Continuous Glucose Monitoring System in the management of type 1 diabetes. Diabetes Metab. 32 2 (2006) 123-129
69. Tanenberg R., Bode B., Lane W., Levetan C., Mestman J., Harmel A.P., et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin. Proc. 79 12 (2004) 1521-1526
70. The Diabetes Research in Children Network (DirecNet) Study Group. A Randomized Multicenter Trial Comparing the GlucoWatch Biographer With Standard Glucose Monitoring in Children With Type 1 Diabetes. Diabetes Care 28 5 (2005) 1101-1106
71. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet. Med. 23 1 (2006) 1-12
72. Mlcak P., Fialova J., Trnkova K., and Chlup R. A Continuous Glucose Monitoring System (CGMS)-a promising approach for improving metabolic control in persons with type 1 diabetes mellitus treated by insulin pumps 863. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 148 1 (2004) 33-38
73. Chetty D.J., and Chien Y.W. Novel methods of insulin delivery: an update. Crit. Rev. Ther. Drug. Carrier Syst. 15 6 (1998) 629-670
74. Schilling R.J., and Mitra A.K. Degradation of insulin by trypsin and alpha-chymotrypsin. Pharm. Res. 8 6 (1991) 721-727
75. Davis S.S. Overcoming barriers to the oral administration of peptide drugs. Trends Pharmacol. Sci. 11 9 (1990) 353-355
76. Crane C.W., and Luntz G.R. Absorption of insulin from the human small intestine. Diabetes 17 10 (1968) 625-627
77. Olsen C., Liu G., and Charles A. Novel routes of insulin delivery. In: Marshall S., and Home P. (Eds). The Diabetes Annual/8 (1994), Elsevier, Amsterdam, London, New York, Tokyo 243-276
78. Hoffman A., and Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin. Pharmacokinet. 33 4 (1997) 285-301
79. Holman R. In: Berger M., and Gries F.A. (Eds). Frontiers in Insulin Pharmacology (1993), Thieme Verlag 138-142
80. Gelfand R.A., Schwartz S., Horton M., Law C.G., and Pun E.F.F. Pharmacological reproducibility of inhaled insulin dosed pre-meal in patients with Type 2 DM. Diabetologia 43 Suppl. 1 (2000) A202
81. Schaffer L., Brissette R.E., Spetzler J.C., Pillutla R.C., Ostergaard S., Lennick M., et al. Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks. Proc. Natl. Acad. Sci. USA 100 8 (2003) 4435-4439
82. McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E., Lovrecz G.O., et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 443 7108 (2006) 218-221
83. Drejer K., Vaag A., Bech K., Hansen P., Sorensen A.R., and Mygind N. Intranasal administration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects. Diabet. Med. 9 4 (1992) 335-340
84. Frauman A.G., Cooper M.E., Parsons B.J., Jerums G., and Louis W.J. Long-term use of intranasal insulin in insulin-dependent diabetic patients. Diabetes Care 10 5 (1987) 573-578
85. Nolte M.S., Taboga C., Salamon E., Moses A., Longenecker J., Flier J., et al. Biological activity of nasally administered insulin in normal subjects. Horm. Metab. Res. 22 3 (1990) 170-174
86. Jacobs M.A., Schreuder R.H., Jap A.J., Nauta J.J., Andersen P.M., and Heine R.J. The pharmacodynamics and activity of intranasally administered insulin in healthy male volunteers. Diabetes 42 11 (1993) 1649-1655
87. Salzman R., Manson J.E., Griffing G.T., Kimmerle R., Ruderman N., McCall A., et al. Intranasal aerosolized insulin. Mixed-meal studies and long-term use in type I diabetes. N. Engl. J. Med. 312 17 (1985) 1078-1084
88. Hilsted J., Madsbad S., Hvidberg A., Rasmussen M.H., Krarup T., Ipsen H., et al. Intranasal insulin therapy: the clinical realities. Diabetologia 38 6 (1995) 680-684
89. Coates P.A., Ismail I.S., Luzio S.D., Griffiths I., Ollerton R.L., Volund A., et al. Intranasal insulin: the effects of three dose regimens on postprandial glycaemic profiles in type II diabetic subjects. Diabet. Med. 12 3 (1995) 235-239
90. Frauman A.G., Jerums G., and Louis W.J. Effects of intranasal insulin in non-obese type II diabetics. Diabetes Res. Clin. Pract. 3 4 (1987) 197-202
91. Gordon G.S., Moses A.C., Silver R.D., Flier J.S., and Carey M.C. Nasal absorption of insulin: enhancement by hydrophobic bile salts. Proc. Natl. Acad. Sci. USA 82 21 (1985) 7419-7423
92. Heinemann L. Alternative delivery routes: inhaled insulin. Diabetes Nutr. Metab. 15 6 (2002) 417-422
93. Gänsslen M. Über inhalation von insulin. Klin Wochensubcutaneoushr 4 (1925) 71
94. Wigley F.W., Londono J.H., Wood S.H., Shipp J.C., and Waldman R.H. Insulin across respiratory mucosae by aerosol delivery. Diabetes 20 8 (1971) 552-556
95. Patton J.S., Bukar J.G., and Eldon M.A. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin. Pharmacokinet. 43 12 (2004) 781-801
96. Fineberg S.E. Diabetes therapy trials with inhaled insulin. Expert Opin. Investig. Drugs 15 7 (2006) 743-762
97. Laube B.L., Georgopoulos A., and Adams III G.K. Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients. JAMA 269 16 (1993) 2106-2109
98. Brunner G.A., Balent B., Ellmerer M., Schaupp L., Siebenhofer A., Jendle J.H., et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 44 3 (2001) 305-308
99. Cefalu W.T., Skyler J.S., Kourides I.A., Landschulz W.H., Balagtas C.C., Cheng S., et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann. Intern. Med. 134 3 (2001) 203-207
100. Skyler J.S., Cefalu W.T., Kourides I.A., Landschulz W.H., Balagtas C.C., Cheng S.L., et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357 9253 (2001) 331-335
101. Adamson U., Rönnemaa T., Petersen A.H., and Hermansen K. Inhaled human insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetologia 45 Suppl. 2 (2002) A255-A256
102. Cefalu W.T., Rosenstock J., and Bindra S. Inhaled insulin: a novel route for insulin delivery. Expert Opin. Investig. Drugs. 11 5 (2002) 687-691